Week in Review: Tasly Pharmaceutical Buys Stake in TCM Maker for $25 Million

by Richard Daverman, PhD

October 5, 2013 --Tianjin Tasly Pharma acquired a 45% stake in Henan New Century Pharmaceutical for $24.7 million; Hefei Life Science Park will fund the China clinical development of a drug eluting stent produced by Micell Technologies, a North Carolina device maker; Sanofi is taking the “big picture” approach to emerging markets, continuing to invest despite drug price reductions and accusations of bribery; Parexel, the US clinical-stage CRO, has formed a Beijing company that is dedicated entirely to conducting trials that will gain product approvals in China; Lee's Pharma of Hong Kong said its China registration study of Trazodone as a treatment for depression met its primary endpoint. More details….

Stock Symbols: (SHA: 600535) (NYSE: SNY) (NSDQ: PRXL) (HK: 0950)

Help employers find you! Check out all the jobs and post your resume.